Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
PureTech Health's Founded Entity, Akili Interactive Labs, has launched a pivotal Phase 3 study of SDT-001, a digital treatment aimed at improving attention in children with ADHD in Japan. This trial follows a successful Phase 2 study showing enhanced attention compared to standard treatments. Approximately 150 participants aged 6-17 will enroll in multiple sites, with results expected in 2H2023. The treatment leverages video game technology designed to engage cognitive functions. Akili's products are already FDA-cleared and CE-marked in the U.S. and Europe for similar indications.
PureTech Health plc (Nasdaq: PRTC) reported positive results from a study of Akili's digital therapeutic AKL-T01 for cognitive dysfunction in patients with Systemic Lupus Erythematosus (SLE). Conducted with 60 participants, the study showed significant improvements in motor speed and executive functions. The EVO™ Monitor also demonstrated its potential for rapid mobile cognitive assessment. This technology could enhance treatment options for approximately 1.5 million SLE patients in the U.S., where cognitive dysfunction affects 20% to 80% of them.
PureTech Health (LSE: PRTC, Nasdaq: PRTC) announced nominees for the board of directors for its Founded Entity, Akili Interactive, following its merger with Social Capital Suvretta Holdings Corp. I (Nasdaq: DNAA). The board will include industry leaders such as BJ Jones, Christine Lemke, Ken Ehlert, and Chamath Palihapitiya, who bring extensive experience in biopharmaceuticals and healthcare. This move marks a significant step toward Akili’s goal of scaling digital therapeutics, particularly as it approaches market introduction of its first product.
Vedanta Biosciences, a clinical-stage biopharmaceutical company, has announced participation in two upcoming investor conferences: the William Blair Biotech Focus Conference on July 12-13, 2022, in New York, and the SVB Securities Biopharma Private Company Connect on July 20-21, 2022, offering virtual 1x1 meetings. The company specializes in pioneering oral therapies using defined bacterial consortia, targeting conditions such as C. difficile infection, inflammatory bowel diseases, and cancer. Vedanta boasts over 45 patents and a vast library of bacteria from the human microbiome.
PureTech Health plc has announced the initiation of a clinical study for LYT-100 (deupirfenidone), a potential treatment for idiopathic pulmonary fibrosis (IPF). This global, randomized study aims to assess the efficacy and tolerability of LYT-100 compared to pirfenidone and a placebo. Approximately 240 patients will participate, with topline results expected by the end of 2023. Additionally, the company is advancing its LYT-200 program for solid tumors, with plans to initiate a leukemia study by year-end 2022.
PureTech Health plc has announced the opening of a new large-scale CGMP facility by its Founded Entity, Vedanta Biosciences, to manufacture clinical and commercial supplies for its microbiome therapies. This facility will support the planned Phase 3 clinical trial and potential commercial launch of VE303, targeted at high-risk Clostridioides difficile infection. With established capabilities to produce defined bacterial consortia in compliance with global standards, Vedanta aims to enhance its leadership in microbiome-based therapies.
Vedanta Biosciences announces the opening of a new multi-product CGMP facility in Cambridge, MA, designed to manufacture oral therapies based on defined bacterial consortia. This facility will support the planned Phase 3 clinical trial and potential commercial launch of VE303 for Clostridioides difficile infection. The facility enhances Vedanta's manufacturing capabilities, ensuring compliance with global regulatory standards and addressing critical production challenges for microbiome-based therapies.
On June 15, 2022, PureTech Health held its Annual General Meeting, where shareholders approved all proposed resolutions. Notable outcomes include 100% approval for the Annual Report and Accounts, and the election of several directors. The vote breakdown for director elections showed high support, with the lowest approval at 95.99%. Shareholders also reappointed KPMG as auditors with 97.82% support and authorized the allotment of shares with 97.90% approval. Overall, the meeting reinforced shareholder confidence in the company's leadership and governance.
PureTech Health announced successful proof-of-principle for its LYT-300, an oral prodrug of allopregnanolone, achieving systemic blood levels approximately nine-fold greater than traditional oral allopregnanolone. This breakthrough is crucial as it aims to deliver the proven efficacy of allopregnanolone via simple oral dosing, overcoming limitations of intravenous delivery. The results validate PureTech's Glyph™ technology platform, designed to enhance oral bioavailability and lymphatic targeting, potentially impacting treatment for various neurological conditions, including postpartum depression.
PureTech Health announced results from a Phase 2 study of LYT-100 (deupirfenidone) in patients with post-acute “Long” COVID, revealing no treatment effect. However, the study reaffirmed LYT-100's strong safety and tolerability profile. PureTech will not pursue further studies in this patient population but will focus on initiating registration-enabling studies for LYT-100 in idiopathic pulmonary fibrosis (IPF) later this month, leveraging previously established efficacy of pirfenidone. The study involved 177 patients and showed meaningful improvements in walking distance for both treatment and placebo groups.